Niprisan (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions

British Journal of Haematology

Volumn 122, Issue 6, 2003, Pages 1001-1008

  Iyamu, Efemwonkiekie W ^a   Turner, Ernest A ^b   Asakura, Toshio ^a,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b ProHealth Medical Center   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antisickling agent; Hypoxia; P50; Sickle cell disease; Transgenic sickle mice

Indexed keywords

NIRPIAM; NIX 0699; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; HISTOLOGY; HISTOPATHOLOGY; MEDICAL EXAMINATION; NONHUMAN; PRIORITY JOURNAL; SICKLE CELL; SICKLE CELL ANEMIA; SURVIVAL RATE; TRANSGENIC MOUSE; VENOUS BLOOD;

ACUTE DISEASE; ANEMIA, SICKLE CELL; ANIMALS; ANOXIA; ANTISICKLING AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; LUNG; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLANT EXTRACTS; SURVIVAL RATE;

EID: 0141428861     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04536.x     Document Type: Article

References (35)

1. Abraham, D.J. & Perutz, M.F. (1986) Development of therapeutic agent for sickle cell disease. In: Approaches to the Therapy of Sickle Cell Anemia (ed. by Y. Beuzard, S. Charache & F. Galacteros), pp. 141-149. INSERM, Paris.
2. Al-khatti, A., Papayannopoulou, T., Knitter, G., Fritsch, E.F. & Stamatoyannopoulos, G. (1988) Co-operative enhancement of F-cell formation in baboons treated with erythropoietin and hydroxyurea. Blood, 72, 817-819.
3. Asakura, T. (1979) Automated method for determination of oxygen equilibrium curves of red cell suspension under controlled buffered conditions and its clinical applications. Critical Care Medicine, 7, 391-395.
4. Asakura, T., Minakata, K., Adachi, K., Russell, M.O. & Schwartz, E. (1977) Denatured haemoglobin in sickle erythrocytes. Journal of Clinical Investigation, 59, 633-640.
5. Asakura, T., Mattiello, J.A., Obata, K., Asakura, K., Reilly, M.P., Tomassini, N., Schwartz, E. & Ohene-Frempong, K. (1994) Partially oxygenated sickled cells: Sickle-shape red cells found in circulating blood of patients with sickle cell disease. Proceeding of the National Academy of Science of the USA, 91, 12589-12593.
6. Ballas, S.K. (1994) Neurobiology and treatment of pain. In: Sickle Cell Disease: Basic Principle and Clinical Practice (ed. by S.H. Erabury, R.P. Hebbel, N. Mohandas & M.H. Steinberg), pp. 217-223. Raven, New York.
7. Beutler, E. (1975) The effect of carbon monoxide on red cell life span in sickle cell disease. Blood, 46, 253-259.
8. Beutler, E. & Mikus, B.J. (1961) The effect of methemoglobin formation in sickle cell disease. Journal of Clinical Investigation, 40, 1857-1871.
9. Charache, S., Dover, G.J., Moore, R.D., Eckert, S., Ballas, S.K., Koshy, M., Milner, P.F., Orringer, E.P., Phillips, Jr, G. & Platt, O.S. (1992) Hydroxyurea: effects on haemoglobin F production in patients with sickle cell anemia. Blood, 79, 2555-2565.
10. Charache, S., Terrin, M.L., Moore, R.D., Dover, G., Barton, F., Eckert, S., Mcmahon, R. & Bonds, D. (1995) Effects of hydroxyurea on the frequency of painful crises in sickle cell anemia and the investigators of the multicenter study of hydroxyurea in sickle cell anemia. New England Journal of Medicine, 332, 1317-1322.
11. De Franceschi, L., Brugnara, C., Rouyer-Fessard, P., Jouault, H. & Beuzard, Y. (1999) Formation of dense erythrocytes in SAD mice exposed to chronic hypoxia: evaluation of different therapeutic regimens and of a combination of oral clotrimazole and magnesium therapies. Blood, 94, 4307-4313.
12. Festa, R.S. & Asakura, T. (1979) The use of oxygen dissociation curve analyser in transfusion therapy. Transfusion, 19, 107-113.
13. Fibach, E., Burk, L.P., Schechter, A.N., Noguchi, C.T. & Rodgers, G.P. (1993) Hydroxyurea increases fetal haemoglobin in cultured erythroids cells derived from normal individuals and patients with sickle cell anemia or thalassemia. Blood, 81, 1630-1635.
14. Hebbel, R.P. & Mohandas, N. (1994) Sickle cell adherence. In: Sickle Cell Disease: Basic Principle and Clinical Practice (ed. by S.H. Embury, R.P. Hebbel, N. Mohandas & M.H. Steinberg), p. 217. Raven, New York.
15. Horiuchi, K., Ohata, J., Hirano, Y. & Asakura, T. (1990) Morphological studies of sickled erythrocytes by image analysis. Journal of Laboratory and Clinical Medicine, 115, 613-620.
16. Iyamu, E.W., Turner, E.A. & Asakura, T.A. (2002) In vitro effects of Niprisan (Nix-0699): a naturally occurring potent anti-sickling agent. British Journal of Haematolgy, 118, 337-343.
17. 3 and von Willebrand factor. In: New Trends in Therapy Sickle Cell Disease and Thalassemias (ed. by Y. Beuzard, B. Lubin & J. Rosa), p. 497. Proceedings of INSERM Symposium, Paris, France.
18. Laszlo, J., Obenour, Jr, W. & Saltzman, H.A. (1969) Effects of hyperbaric oxygenation on sickle syndromes. Southern Medical Journal, 62, 453-456.
19. Lechner, A.J. (1978) The scaling of maximum oxygen consumption and pulmonary dimensions in small mammals. Respiratory Physiology, 34, 29-44.
20. Ley, T.J. (1991) The pharmacology of haemoglobin switching of mice and men. Blood, 77, 1146-1152.
21. Lin, Y.M., Raffen, R., Zhou, Y., Cassidy, C.S., Flavin, M.T. & Stevens, F. (2001) Amyloid fibril formation in microwell plates for screening of inhibitors. Amyloid, 8, 182-193.
22. Ono, K., Hasegawa, K., Yamada, M. & Naiki, H. (2002) Nicotine breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro. Biological Psychiatry, 52, 880-886.
23. Orringer, E.P., Abraham, D.J. & Parker, J.C. (1994) Development of drug therapy. In: Sickle Cell Disease: Basic Principle and Clinical Practice (ed. by S.H. Embury, R.P. Hebbel, N. Mohandas & M.H. Steinberg), pp. 861-871. Raven, New York.
24. Palek, J., Liu, A., Liu, D., Snyder, L.M., Fortier, N.L., Njoku, G., Kiernan, F., Funk, D. & Crusberg, T. (1977) Effect of procaine HCL on ATP: calcium-dependent alterations in red cell shape and deformability. Blood, 50, 155-164.
25. Parkhurst, L.J. (1979) Haemoglobin and myoglobin ligand kinetics. Annual Review of Physical Chemistry, 30, 509.
26. Perrine, S.P., Ginder, G.D., Faller, D.V., Dover, G.H., Ikuta, T., Witkowska, H.E., Cai, S.P., Vichinsky, E.P. & Olivieri, N.F. (1993) A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. New England Journal of Medicine, 328, 81-86.
27. Peters, R.H. (1986) Ecological Implications of Body Size, 2nd edn, pp. 50-51. Cambridge University Press, New York.
28. Reilly, M.P., Chomo, M.J., Obata, K. & Asakura, T. (1994) Red blood cell membrane and density changes under ambient and hypoxic conditions in transgenic mice producing human sickle haemoglobin. Experimental Hematology, 22, 501-509.
29. Ryan, T.M., Townes, T.M., Reilly, M.P., Asakura, T., Palmiter, R.D., Brinster, R.L. & Behringer, R.R. (1990) Human sickle haemoglobin in transgenic mice. Science, 247, 566-568.
30. Schmidt-Nielsen, K. (1984) Scaling: Why Animal Size Is Important, pp. 119-121. Cambridge University Press, New York.
31. Silva, M.M., Santos, M.R., Caroco, G., Rocha, R., Justino, G. & Mira, L. (2002) Structure-antioxidant activity relationships of flavonoids: a re-examination. Free Radical Research, 36, 1219-1227.
32. Trudel, M., De Paepe, M.E., Chretien, N., Saadane, N., Jacmain, J., Sorette, M., Hoang, T. & Beuzard, Y. (1994) Sickle cell disease of SAD mice. Blood, 84, 3189-3197.
33. Uchida, K., Reilly, M.P. & Asakura, T. (1998) Molecular and function of mouse hemoglobins. Zoological Sciences, 15, 703-706.
34. Wambebe, C.O., Bamgboye, E.A., Bardu, B.O., Khamofu, H., Momoh, J.A., Ekpeyong, M., Audu, B.S., Njoku, S.O., Nasipuri, N.R., Kunle, O.O., Okogun, J.I., Enwerem, N.M., Gamaliel, S.K., Obodozie, O.O., Samuel, B., Fojule, G. & Ogunyale, P.O. (2001a) Efficacy of Niprisan in the prophylactic management of patients with sickle cell disease. Current Therapeutic Research, 62, 26-34.
35. Wambebe, C., Khamofu, H., Momoh, J.A., Ekpeyong, M., Audu, B.S., Njoku, O.S., Bamgboye, E.A., Nasipuri, R.N., Kunle, O.O., Okogun, J.I., Enwerem, M.N., Audam, J.G., Gamaniel, K.S., Obodozie, O.O., Samuel, B., Fojule, G. & Ogunyale, O. (2001b) Double-blind, placebo-controlled, randomised cross-over clinical trial of Niprisan in patients with sickle cell disorder. Phytomedicine, 8, 252-261.